A Guide to Navigating the Complexities of Cell and Gene Therapy (CAGT)
Cell and gene therapy (CAGT) is revolutionizing medicine, offering potentially curative treatments for diseases such as genetic disorders and cancers. With the global CAGT market valued at $30.27 billion in 2024 and projecting a remarkable compound annual growth rate (CAGR) of 22.7% through 2033, the industry is poised for unprecedented growth and innovation.
For companies looking to enter or expand within the CAGT space, understanding the landscape and its inherent challenges is crucial for success. This article will offer insights and explore key considerations for navigating the complexities of CAGT development.
Understanding the CAGT landscape
This rapidly evolving field encompasses a diverse range of therapeutic approaches, each with unique requirements. The advancement in CAGT trials is evidenced by the US Food and Drug Administration (FDA)'s approval of 43 therapies as of December 2024, with seven in 2024 alone. This momentum reflects the growing confidence in CAGT's therapeutic potential and the evolving regulatory framework supporting its development.
The FDA is not alone in shaping this regulatory landscape. Global regulatory bodies worldwide are collaborating to define the future of CAGT regulation through platforms such as the World Health Organization and the International Council for Harmonization. Inspired by Project Orbis (an oncology initiative), the FDA's innovative CoGenT pilot program represents a significant step toward streamlining CAGT development and regulatory review processes globally.
Key challenges and strategies in CAGT development
Making pivotal decisions early at the CAGT development stage is critical. Some key regulatory considerations for CAGT clinical development include:
- Regulatory and ethics approvals: Jurisdictional differences can extend timelines and complicate dossier requirements.
- Environmental release and approvals: Preparing in advance is essential to address national and local expectations on environmental release, impact, and site-level.
- Additional documentation: Developers should anticipate the need for unique documentation requirements specific to CAGTs in the development phase.
- Longer safety follow-up: Trials may require extended safety follow-up periods, potentially lasting up to 15 years. This demands thorough planning and resource allocation to address regulatory expectations for long-term durability of effect and safety.
Despite CAGT’s immense potential, the path to successful development is fraught with challenges. Many programs face early-stage hurdles due to operational models, manufacturing complexities, curative dose, and mechanisms of action required for different therapies. These unique demands converge into four key challenge areas:
- Trial design: Streamlining trials to reduce patient burden and maximizing retention is paramount. Key considerations include defining the target population, designing the trial with future label expansion in mind, and incorporating patient voices.
- Patient and Site Identification: Minimizing screen failures and developing sustainable patient identification strategies are crucial. This involves leveraging registries, pre-screening protocols, and partnerships with patient advocacy groups. A well-defined country and site strategy is also essential, encompassing navigating regulatory hurdles and accessing diverse patient populations.
- Trial Execution: Addressing manufacturing and logistical challenges early is critical to securing scalability for late-stage development. This includes mapping processes to identify roadblocks, understanding regulatory requirements and therapy administration, and harmonizing patient journeys.
- Long-Term Follow-Up: Given that follow-up CAGT studies may extend up to 15 years, developing comprehensive, patient-centric solutions are important to minimize stakeholder burden in addition to implementing strategies to reduce frequency of visits, remote consultation and simplify data collection.
Stringent protocols throughout the supply chain, varying cold chain requirements, and geographically diverse sites create significant logistical complexities for CAGT trials. Engaging multi-specialty vendors is crucial to effectively manage the logistical intricacies of biospecimen and resource management. Logistics and supply chain management strategies are dictated by the specific therapy type, manufacturing location, and number of patients involved.
The Asia Pacific Opportunity
The Asia Pacific (APAC) region is emerging as a dynamic frontier for CAGT development, with countries like China, Japan, South Korea, Australia, and New Zealand as key players. Australia, with its established regulatory framework and expertise, sets a “gold standard” for running CAGT trials. There are eight approved treatment centers providing commercially available CAR-T cell therapies. The country's robust regulatory framework and expertise provide a solid foundation for clinical development.
While New Zealand has limited CAGT therapies, the absence of commercially available CAR-T cell therapies present significant growth opportunities. Diego Correa, Vice President and Global Head, CAGT Center of Excellence of IQVIA Biotech, shared, “Elements critical for CAGT are clinical expertise, basic science expertise, and innovation to expedite clinical development. The most important is manufacturing which plays an instrumental role in operations. Organizations like the Viral Vector Manufacturing Facility may help mitigate associated risks”. Already delivering over 185 trials in the CAGT space, country investigators, hospitals and logistics are ready to take on new advanced therapies to improve the outlook of ANZ patients.
Japan has made strides with approximately 45 CAR-T cell accredited centers, while South Korea has positioned itself as a global leader in approved cell therapies, driven by strong government partnerships with domestic manufacturers. Singapore is the first market in Southeast Asia to receive regulatory approvals for CAR-T but public funding remains limited. As for Malaysia and Thailand, CAR-T is currently undergoing advanced stages of clinical trials and used on a case-by-case basis.
While APAC holds immense potential, many markets in the region remain largely underdeveloped in terms of CAGT trial settings, creating both challenges and opportunities for future growth.
Looking Ahead
Success in this complex landscape requires a holistic approach that combines deep therapeutic expertise with operational excellence. Organizations must navigate not only the scientific and technical challenges but also the unique regulatory and cultural nuances of each market. As the CAGT field continues to evolve, the APAC region will play an increasingly important role in advancing these innovative therapies and improving patient access to potentially life-changing treatments.
IQVIA understands the complexities of CAGT development and combines data-driven insights, innovative technologies, and exceptional expertise to help drive smarter decisions and accelerate clinical trials. Through its CAGT Center of Excellence, IQVIA provides end-to-end solutions to help navigate operational challenges, from pre-clinical to commercial stage.
To learn more about navigating the complexities of CAGT, watch IQVIA’s webinar series and see how IQVIA can support a seamless CAGT clinical development journey.
